



US007566539B2

(12) **United States Patent**  
**LaRosa**(10) **Patent No.:** **US 7,566,539 B2**  
(45) **Date of Patent:** **Jul. 28, 2009**(54) **ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR**(75) Inventor: **Gregory J LaRosa, Newton, MA (US)**(73) Assignee: **Millennium Pharmaceuticals, Inc., Cambridge, MA (US)**

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 353 days.

(21) Appl. No.: **10/656,805**(22) Filed: **Sep. 5, 2003**(65) **Prior Publication Data**

US 2005/0048052 A1 Mar. 3, 2005

**Related U.S. Application Data**

(63) Continuation of application No. 09/898,513, filed on Jul. 3, 2001, now abandoned, which is a continuation of application No. 09/121,781, filed on Jul. 23, 1998, now Pat. No. 6,312,689.

(51) **Int. Cl.****G01N 33/53** (2006.01)**G01N 33/567** (2006.01)**G01N 33/574** (2006.01)**C07K 17/00** (2006.01)(52) **U.S. Cl.** ..... 435/7.1; 435/7.2; 435/7.21; 435/7.23(58) **Field of Classification Search** ..... None  
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**

4,816,397 A 3/1989 Boss et al.  
4,816,567 A 3/1989 Cabilly et al.  
5,225,539 A 7/1993 Winter  
5,440,021 A 8/1995 Chuntharapai et al.  
5,543,503 A 8/1996 Chuntharapai et al.  
5,571,713 A 11/1996 Lyle et al.  
5,585,089 A 12/1996 Queen et al.  
5,657,277 A 8/1997 Shirley  
5,693,761 A 12/1997 Queen et al.  
5,693,762 A 12/1997 Queen et al.  
5,707,815 A 1/1998 Charo et al.  
5,808,960 A 9/1998 McClure  
5,858,089 A \* 1/1999 Martinovic ..... 118/13  
5,859,205 A 1/1999 Adair et al.  
5,985,279 A 11/1999 Waldmann et al.  
6,006,339 A 12/1999 McClure  
6,075,181 A \* 6/2000 Kucherlapati et al. .... 800/25  
6,084,075 A \* 7/2000 Lind et al. .... 530/388.22  
6,312,689 B1 11/2001 LaRosa  
6,352,832 B1 3/2002 LaRosa et al.  
6,395,497 B1 5/2002 LaRosa  
6,406,694 B1 6/2002 LaRosa  
6,406,865 B2 6/2002 LaRosa  
6,448,021 B1 9/2002 LaRosa  
6,451,522 B2 9/2002 LaRosa  
6,458,353 B1 10/2002 LaRosa  
6,491,915 B2 12/2002 LaRosa

6,696,550 B2 2/2004 LaRosa et al.  
7,053,202 B2 5/2006 O'Keefe et al.  
2003/0165494 A1 9/2003 LaRosa et al.  
2004/0126851 A1 7/2004 LaRosa et al.  
2004/0132980 A1 7/2004 LaRosa et al.  
2004/0151721 A1 8/2004 O'Keefe et al.  
2004/0265303 A1 12/2004 LaRosa et al.  
2006/0147445 A1 7/2006 O'Keefe et al.

**FOREIGN PATENT DOCUMENTS**

WO WO 91/09967 7/1991  
WO WO 94/09128 4/1994  
WO WO 94/12214 6/1994  
WO WO 95/08576 3/1995  
WO WO 95/19436 7/1995  
WO WO 97/31949 \* 9/1997  
WO WO 97/47319 12/1997  
WO WO 98/42360 10/1998  
WO WO 98/44953 10/1998  
WO WO 99/15666 4/1999  
WO WO 00/05265 2/2000

**OTHER PUBLICATIONS**

Lederman et al. *Molecular Immunology*, 1991, 28;11:1171-1181.\*  
Li et al. *PNAS*, 1980, 77;6:3211-3214.\*  
Frade et al. *The Journal of Immunology* 1997, 159:5576-5584.\*  
Li et al. *Biochemistry* 2000, 39;6:296-309.\*  
Förster, R., et al., "A general method for screening mAbs specific for G-protein coupled receptors as exemplified by using epitope tagged BLR1-transfected 293 cells and solid-phase cell ELISA", *Biochemical and Biophysical Research Communications*, 196(3):1496-1503 (1993).  
Boring, L., et al., "Decreased lesion formation in CCR2<sup>-/-</sup> mice reveals a role for chemokines in the initiation of atherosclerosis," *Nature*, 394(27):894-897 (1998).  
Ylä-Herttuala, S., et al., "Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions," *Proc. Natl. Acad. Sci., USA* 88:5252-5256 (1991).  
Taubman, M.B., et al., "JE mRNA Accumulates Rapidly in Aortic Injury and in Platelet-Derived Growth Factor-Stimulated Vascular Smooth Muscle Cells," *Circulation Research* 70(2):314-325 (1992).  
Feng, A., et al., "Red Wine Inhibits Monocyte Chemoattractant Protein-1 Expression and Modestly Reduces Neointimal Hyperplasia After Balloon Injury in Cholesterol-Fed Rabbits," *Circulation* 100:2254-2259 (1999).

(Continued)

*Primary Examiner*—Maher M Haddad  
*Assistant Examiner*—Chun Dahle  
(74) *Attorney, Agent, or Firm*—Lando & Anastasi, LLP

(57) **ABSTRACT**

The present invention relates to an antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.